SUVND-4010 is under clinical development by Suven Life Sciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SUVND-4010’s likelihood of approval (LoA) and phase transition for Cognitive Impairment Associated With Schizophrenia (CIAS) took place on 14 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SUVND-4010 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SUVND-4010 overview

SUVND-4010 (SUVN-D1108121) is under development for the treatment of cognitive dysfunction associated with Alzheimer’s disease and schizophrenia. It is administered orally in the form of tablet. The drug candidate is a new chemical entity, it acts by targeting 5-HT4 receptor. 

Suven Life Sciences overview

Suven Life Sciences (Suven), formerly Suven Pharmaceuticals is a company that designs, develops, manufactures, and supplies bulk actives, drug intermediates, and fine chemicals. The company offers active pharmaceutical ingredient products which include aripiprazole, calcium acetate, divalproex sodium, entacapone, fenoprofen calcium, gabapentin, glycopyrrolate, and others. It provides iron sucrose complex for injection, losartan potassium, malathion lotion, nitazoxanide and pamabrom. Suven’s intermediates include diethyl amino cyanoacetamide, dihydroxy nitrobenzaldehyde, triacetoxy deoxyribose and cyclobutanecarbonitrile. The company offers products in form of solutions, suspensions, emulsions, injectables, lyophilized formulations, ophthalmic and oral preparations, ointments, creams, and gels. The company operates in the US, Australia, India, and New Zealand. Suven is headquartered in Hyderabad, Telangana, India.

Quick View SUVND-4010 LOA Data

Report Segments
  • Innovator
Drug Name
  • SUVND-4010
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.